Search
Uteroglobin
go.drugbank.com/drugs/DB14880InvestigationalUteroglobin is under investigation in clinical trial NCT01473264 (Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)).
PF-04691502
go.drugbank.com/drugs/DB11974InvestigationalPF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).
Alemtuzumab
go.drugbank.com/drugs/DB00087ApprovedInvestigationalThe Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G).
Pheniprazine
go.drugbank.com/drugs/DB09250ApprovedWithdrawnPheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis. … Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant in the 1960s.
Phenelzine
go.drugbank.com/drugs/DB00780ApprovedInvestigationalPhenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA ap...
Categories: Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2C19 InhibitorsPhenyl salicylate
go.drugbank.com/drugs/DB11071ApprovedIt is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in [DB00945] ). … These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure
Mixtures: Urin D/S, Prosed/DSCyclizine
go.drugbank.com/drugs/DB01176ApprovedWithdrawnA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsDDP-200
go.drugbank.com/drugs/DB05919ExperimentalDDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.
Elranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigationalIt is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one
Synonyms: ANTI-CD3/ANTI-BCMA BISPECIFIC MONOCLONAL ANTIBODY PF-06863135, -CHAIN) (HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .GAMMA.2-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .KAPPA.-CHAIN, (223->217')(2Allylestrenol
go.drugbank.com/drugs/DB01431InvestigationalA synthetic steroid with progestational activity. It is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates